Compared with younger people, elderly people show age-related sleep changes, including an advanced sleep phase and decreased slow-wave sleep, which result in fragmented sleep and early awakening. Multiple etiologies contribute to insomnia in the elderly, consistent with the observation that elderly people are likely to have comorbid conditions and medications. When elderly individuals complain of insomnia, it is important to assess treatable medical conditions and medication use that may be responsible for the insomnia before the use of hypnotics is initiated. Also, screening for primary sleep disorders, such as sleep apnea syndrome, restless legs syndrome and rapid eye movement sleep behavior disorder, is essential. We review sleep disorders commonly observed in the elderly and describe their diagnosis and management.
insomnia should also be checked. Loss of appetite and interest in addition to insomnia may suggest depression. In addition, delirium related to dementia, anxiety disorders, alcoholism, psychological factors, and life events (loneliness, the death of a partner/spouse or hospitalization) may also cause insomnia in the elderly. Habitual snoring and witnessed apnea during sleep are signs of obstructive sleep apnea (OSA). Greater functional impairment is more strongly associated with older subjects with insomnia comorbid with SAS than with those having neither insomnia nor SAS. 10 Sleep-initiation and/or maintenance problems that are accompanied by restlessness of the legs should prompt evaluation for RLS. RBD should be suspected when nocturnal vocalization, sleep talking, and abnormal movements or behavior related to dream content are witnessed by a bed partner. In this review, we describe sleep disturbances commonly observed in older people as well as their causes and treatment.
| PHYSIOLOGY OF SLEEP AND AGE-RELATED CHANGES IN SLEEP
The human 24-hour sleep/wake cycle is tightly regulated by the circadian master clock located in the suprachiasmatic nuclei of the hypothalamus; this clock is synchronized by external entrainers such as light and food. It is well known that on the day after sleep loss, more sleep is needed to compensate (homeostatic sleep pressure). Thus, the homeostatic system promotes the amount of sleep we need, whereas the circadian system optimizes the best timing to sleep. 11 The suprachiasmatic nucleus regulates melatonin secretion by the pineal gland. 12 Melatonin modifies circadian rhythm and signals day-night transitions. Melatonin levels in the pineal gland are low during the daytime and increase after the onset of darkness (9-10 pm), reaching peak levels when it is darkest (3-5 am).
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The two-process model of sleep regulation, which has been used to explain 24-hour sleep regulation in humans, includes the following: Process S, which is entirely determined by the temporal sequence of behavioral states; and Process C, which is totally controlled by the circadian pacemaker, irrespective of behavioral state. 15 In the elderly, reduced homeostatic sleep pressure decreases the amount of slow-wave sleep. 16 Additionally, reduced circadian signals in the elderly result in reduced core body temperature and a phase advance of wake and sleep times.
Sleep is divided into non-rapid eye movement (NREM) and REM sleep. NREM sleep is further divided into light sleep (stages N1 and N2) and slow-wave sleep (stage N3). 6 REM sleep occurs periodically in cycles of approximately 90-120 minutes of sleep. In polysomnographic studies, four consistent changes related to aging are observed:
decreased total sleep time, sleep efficiency, and slow-wave sleep; and increased waking after sleep onset. 17 A meta-analysis of 3577 subjects aged 5-102 years demonstrated age-related changes in sleep architecture ( Figure 1 ). 17 In adults, total sleep time, sleep efficiency, percentage of slow-wave sleep, percentage of REM sleep, and REM latency all decreased with age. Sleep latency increased with age, but this change was very subtle. Only sleep efficiency continued to decrease after 60 years of age.
| DIAGNOSTIC CRITERIA OF INSOMNIA DISORDER
Insomnia is a subjective sleep problem that is typically defined by difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunities and situations for sleep.
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T A B L E 1 Causes of chronic insomnia in older people (modified from ref. requires a duration of at least 3 months for a diagnosis of insomnia.
Therefore, depending on the insomnia criteria used, the prevalence of insomnia can vary widely: The reported prevalence of insomnia among adults was 15% and 4% according to the ICSD-2 and ICD-10, respectively. 6 
| INSOMNIA IN THE ELDERLY
In elderly individuals, sleep-maintenance insomnia and early awakening are more common complaints than sleep-onset insomnia; this is likely due to the age-related changes in sleep architecture and circadian rhythm described above. 21 Unruh et al. other risk factors for falls. Although the results remain controversial, 26 Morimoto et al. 27 demonstrated that obstructive, central, and mixed SAS were associated with an increased risk of cardiovascularrelated and all-cause mortality. Elderly participants with persistent insomnia have also been reported to have an increased risk for developing depression. 28 Despite the fact that sleep becomes increasingly or metabolic disorders such as hypoglycemia due to insulinoma should be ruled out (Table 3) . 30 NREM parasomnia is common in younger subjects, whereas REM parasomnia, such as RBD, is common in subjects aged 50 years or older. The RBD screening questionnaire (RBDSQ) is a widely used, 31 including in Japan, 32 and useful way of screening for RBD (a cutoff RBDSQ score ≥5 suggests probable RBD).
| MANAGEMENT OF INSOMNIA
There are both nonpharmacological approaches and pharmacological treatments for insomnia. Sleep hygiene education should be the first approach because the development of good sleep habits benefits all insomnia sufferers. As mentioned previously, when other sleep disorders or mental/physical illnesses related to insomnia are suspected, prompt screening for each condition is needed. In parallel, treatment for insomnia is recommended; it is not necessary to wait for a response to treatment for comorbid conditions. However, the use of benzodiazepines should be avoided when severe SAS is strongly suspected, as these drugs aggravate sleep apnea. Also, antidepressants such as selective serotonin reuptake inhibitors can worsen or trigger RLS or RBD. Good sleep hygiene includes regular exercise and meals, the avoidance of stimulants such as caffeine and tobacco, and the creation of a comfortable sleep environment (Table 4) . 33 Table 5 lists nonpharmacological treatments for insomnia in the elderly, including stimulus control, sleep restriction, and cognitive behavioral therapy for insomnia (CBT-I). CBT-I has been shown to be useful in elderly subjects, 34 although in Japan, CBT-I is available in a limited number of facilities. Insomnia can co-occur with medical diseases, which sometimes result in secondary insomnia, and in these cases, it is important to treat the primary disease. However, all subtypes of insomnia disorders are included in the ICSD-3 classification of chronic insomnia disorders, without any differentiation between secondary insomnia and primary insomnia, suggesting that treatment of insomnia should be initiated along with treatment for comorbid diseases, rather than waiting to determine the effect that treating the primary disease has on the insomnia. If left untreated, insomnia is known to have a negative impact on the quality of life of sufferers.
When nonpharmacological strategies do not work well, pharmacological treatments should be considered. Hypnotic drugs should be used in the lowest effective dose, and short-term use is recommended. The hypnotics available in Japan are listed in Table 6 . to all GABA A receptors (α1-, α2-, α3-, and α5-containing subtypes).
In contrast, nonbenzodiazepine hypnotics (zolpidem, zopiclone, and eszopiclone) preferentially bind α1-containing subtypes, and the shorter half-life of the effects of binding to these receptors lowers the risk of fall and residual sleepiness. 35 In a recent randomized placebocontrolled study that was conducted over 12 months of observation and included 89 patients with primary insomnia, 10 mg/day zolpidem significantly increased sleep efficiency and reduced sleep latency and waking after sleep onset. There were also no differences in efficacy between women and men, and rebound insomnia and dose escalation were also absent. 36 Eszopiclone has been reported to be efficacious in treating patients with insomnia with comorbid diseases such as depression 37 and Parkinson's disease. 38 Compared to nonbenzodiazepine drugs, benzodiazepine drugs have more anxiolytic effects, which are dependent on the integrity of the α2 subunit, but postwithdrawal rebound, tolerance, and dependence are more important issues. 39 Although the association between the use of hypnotics and the subsequent risk of dementia is inconclusive, several studies have demonstrated an association between the use of benzodiazepines and subsequent dementia. In prospective studies that included older people, long-term use of benzodiazepines was related to an increased risk of dementia (odds ratio 1.6-3.5). 40, 41 In addition, over 8 years of follow-up of 8204 people aged 65 or greater, Shash et al. 42 showed that the use of long-half-life benzodiazepine was associated with an increased risk of dementia (adjusted hazard ratio=1.62; 95% CI, 1.11-2.37). However, because untreated insomnia can impair daytime Limit fluid intake before bedtime to reduce the frequency of urination during sleep. In cases of cerebral infarction or angina pectoris, follow the instructions of your primary physician.
(5) Avoid caffeine Caffeine intake before bedtime may result in sleep-initiation and maintenance problems. Limit caffeinated foods and beverages (Green tea, tea, coffee, cola, and chocolate) to the equivalent of three cups of coffee and ingest them no later than 4 h before bedtime.
(6) Avoid alcohol Limit alcoholic beverages, which may promote sleep initiation but cause fragmented and unrefreshing sleep. 
T A B L E 5 Nonpharmacological treatments for insomnia in the elderly (modified from ref. 33)
Stimulus control Ask patients to go to bed only when sleepy. The bed should be used for sleep only. If the patient is unable to fall asleep for 20 min, suggest they get up and go to another room to do something. The patient can go back to the bedroom when sleepy. The patient should get up at the same time every morning, irrespective of how much sleep the patient had during the night. Avoid naps.
Sleep restriction
Patients should be instructed to sleep for the average total sleep time estimated from a 2-week sleep diary (minimum 4.5 h). Sleep efficiency, as defined by total sleep time/time spent in bed, should be evaluated regularly. When sleep efficiency improves, the time spent in bed can be increased. When sleep efficiency is >90%, the patient go to bed 15 min earlier.
Sleep hygiene (see Table 4 ) For good sleep habits, several tips are recommended: regular exercise and meals, the avoidance of stimulants such as caffeine and tobacco, and the creation of a comfortable sleep environment. Ramelteon has been shown to be effective in treating sleep-onset insomnia and delayed sleep phase syndrome. Its half-life is short (0.83-1.90 hours); however, its effects in reducing wakefulness last up to 6 hours. 11, 44 Ramelteon has been reported to be useful in improving sleep-onset latency in OSA patients treated with auto-titrating positive airway pressure therapy. 45 Additionally, the administration of 8 mg/day ramelteon for 7 days to elderly patients admitted for acute care protected against the occurrence of delirium in a multicenter, rater-blinded, randomized, placebo-controlled setting. 46 Suvorexant, a dual orexin receptor antagonist, is a new class of hypnotic that works by selectively blocking the binding of the wakefulness-promoting neuropeptides orexin A and B to OX1 and OX2 receptors, which suppresses wakefulness. 47 Suvorexant has a half-life of approximately 12 hours and is useful in subjects with sleep-onset as well as sleep-maintenance insomnia. There was no evidence of withdrawal or rebound effects upon discontinuation after up to 1 year of treatment. Based on the drug's mechanism of action, a benign side effect profile has been suggested. 48 The administration of 30-40 mg/day suvorexant (up to twice the maximum recommended dose for treating insomnia in the USA and Japan) in patients with mild-to-moderate chronic obstructive pulmonary disease 49 or mild-to-moderate OSA 50 did not have a detrimental effect on respiratory status as measured by SpO2 or the apnea hypopnea index (AHI).
| PRIMARY SLEEP DISORDERS AND ITS MANAGEMENT

| Rapid eye movement sleep behavior disorder
Rapid eye movement sleep behavior disorder is a parasomnia that occurs during REM sleep and is characterized by dream-enacting behavior, which is the acting out of dream content, including talking, 8% of idiopathic RBD subjects did not recall unpleasant dreams, and 46% were unaware of their abnormal night behavior. 52 Additionally, in patients with RBD, the details of dreams can be almost forgotten by noon the following day. 51 The prevalence of RBD has been estimated as 0.5% of the general population. 53 In a large, random-sample survey of 19 961 members of the general population of Finland, Germany, Italy, Portugal, Spain, and the United Kingdom who were T A B L E 6 Pharmacological treatment for insomnia: primary hypnotic drugs available in Japan 15 years and older, 1.6% of the respondents reported violent behavior during sleep; 78.7% of these individuals reported vivid dreams, and 31.4% hurt themselves or someone else. 54 A study of 349 elderly inpatients and outpatients at the University of Hong Kong identified 2 (0.57%) with RBD based on polysomnographic findings. 55 In a recent study of 488 subjects aged 60-97 years (without Parkinson's disease)
representative of the general elderly community, the prevalence of probable RBD was 4.6% and 7.7% according to the RBD screening questionnaire and Innsbruck RBD-Inventory, respectively. 56 RBD is more common in males and usually occurs after 50 years of age. Earlyonset RBD (onset before 50 years of age) has been associated with increased gender parity, an increased proportion of idiopathic RBD and an increased occurrence of narcolepsy and antidepressant use. 57 It is becoming increasingly clear that 50% of idiopathic patients with RBD convert to a parkinsonian disorder within a decade and that 81%-90% patients with RBD eventually develop a neurodegenerative disorder. 58 Older patients with RBD should be regularly evaluated for the presence of subtle parkinsonism and cognitive and olfactory impairment. 59 In the USA and Europe, 3-12 mg melatonin at bedtime has had clinical efficacy in treating RBD with a reduced risk of fall. 60 The efficacy of the herbal medicine Yi-Gan San has also been reported in Japan. 2 Excessive motor activity in the lower extremities, such as pacing, fidgeting, repetitive kicking, tossing and turning in bed, slapping the legs on the mattress, cycling movements of the lower limbs, repetitive foot tapping, rubbing the feet together, and the inability to remain seated, are present.
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Signs of leg discomfort are exclusively present or worsen during periods of rest or inactivity.
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Signs of leg discomfort are diminished with activity. symptoms (the urge to move the legs and any accompanying unpleasant sensations) begin or worsen during periods of inactivity; (iii) the symptoms are partially or totally relieved by movement; and (iv) the symptoms occur only in the evening or at night or are worse during these times. The latest criteria of the IRLSSG added as a fifth criterion that other conditions or diseases that mimic RLS be ruled out (Table 7) . 62 Clinical features that support a RLS diagnosis include family history of RLS (more than 50% of patients with RLS have a family history of RLS), a favorable response to dopaminergic treatment, the presence of periodic limb movements during sleep or resting wakefulness, and the lack of profound daytime sleepiness. Despite significant sleep loss, patients with RLS rarely report daytime sleepiness. 64 Using proton magnetic resonance spectroscopy, Allen et al. 65 found increased thalamic glutamate levels in patients with RLS that were correlated with wake times during the sleep period, supporting the concept that the hyperarousal state that characterizes RLS is mediated by a nondopaminergic system. When RLS affects older people who are cognitively impaired, the assessment of symptoms and clinical diagnosis are challenging. Table 8 shows diagnostic criteria for probable RLS in the cognitively impaired elderly. 63 An urge to move the legs is suggested when patients rub their legs or exhibit excessive motor activity.
Supporting criteria such as dopaminergic responsiveness, significant
sleep-onset problems, and family history of RLS may also be useful.
Iron replacement therapy should be considered for RLS treatment when serum ferritin levels are lower than 50 μg/L, even if patients do not have iron deficiency anemia. Low-dose dopamine agonists, such as pramipexole and the rotigotine patch, are effective. Additionally, alpha-2 delta ligands, such as gabapentin, pregabalin, and gabapentin enacarbil, are effective. Opioids may be alternatively used in severe cases.
| Sleep apnea syndrome
Among the forms of SAS, OSA is more common in the general population, including the elderly. When central sleep apnea or Cheyne-Stokes respiration is identified, screening for cardiac and cerebrovascular disease should be performed. OSA is associated with metabolic syndrome, diabetes, hypertension, and cardiovascular events. 66, 67 Patients with moderate-to-severe OSA experience an independently increased risk for all-cause mortality and stroke; 68, 69 however, adequate use of long-term CPAP therapy improves cardiovascular outcomes. 70 In a study of 5615 community-dwelling men and women between 40-98 years of age, sleep apnea was found to be common in subjects aged 60 years or older (approximately 50%
had an AHI of 5-14, and approximately 20% had an AHI≥15). 71 In this study, breathing pauses and obesity were insensitive detectors of sleep apnea in older subjects, likely due to the increased upper airway collapsibility in older subjects compared to younger subjects. 6 In a study of 99 older adults and 100 controls, the presence of insomnia symptoms and SAS (AHI≥15) was associated with lower daytime functioning and longer psychomotor reaction times. 10 Oral appliances and CPAP therapy are used for mild and severe OSA, respectively. For overweight to obese subjects, diet and regular exercise should be recommended.
| CONCLUSION
Here, we reviewed and discussed the differential diagnosis, clinical diagnosis, and management of insomnia in elderly subjects. In elderly subjects, the effects on sleep of many comorbid medical conditions, concomitant medication use, and age-related physiological changes in sleep architecture and circadian rhythm should be considered.
Comprehensive assessment and management of insomnia along with treatment of comorbid medical conditions may improve the patient's quality of sleep as well as of daytime life.
